News & Updates
Filter by Specialty:
The role of apixaban in managing venous thromboembolism
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), carries a significant morbidity risk. Risk factors for VTE include surgery, hospitalization, pregnancy, contraceptive use, older age, overweight, and obesity. Dr Lee Yuh Shan, a haematologist at Gleneagles Hospital and Mount Elizabeth Novena Hospital, Singapore, explains how newer drugs such as apixaban (Eliquis, Pfizer) address the challenges posed by conventional VTE management therapies.
The role of apixaban in managing venous thromboembolism
01 Oct 2021
Severe hypoglycaemia ups risk of adverse outcomes in older patients
Severe hypoglycaemia is a risk factor for hospitalization and mortality among older patients with diabetes, a study reports. The event may also serve as a marker of future cardiovascular events among those with pre-existing heart disease and obesity.
Severe hypoglycaemia ups risk of adverse outcomes in older patients
01 Oct 2021
VO2 improvements after cardiac rehabilitation tied to better outcomes in high-risk HF
Higher-risk heart failure (HF) patients who show improvements in peak oxygen consumption (VO2) following cardiac rehabilitation (CR) have lower risks of new-onset atrial arrhythmias, mortality, and hospitalization due to HF exacerbation, a recent study has found.
VO2 improvements after cardiac rehabilitation tied to better outcomes in high-risk HF
01 Oct 2021
Blood pressure variability implicated in dementia risk
Individuals with higher blood pressure (BP) variability are at increased risk of developing probable dementia despite good BP control, according to a post hoc analysis of the SPRINT MIND* trial.
Blood pressure variability implicated in dementia risk
01 Oct 2021
Blood biomarkers allow assessment of mortality risk in acute aortic dissection
Preoperative levels of D-dimer and white blood cells are risk factors for in-hospital mortality in patients with type A acute aortic dissection, a recent study has found.
Blood biomarkers allow assessment of mortality risk in acute aortic dissection
29 Sep 2021
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
In the treatment of patients with type 2 diabetes mellitus and hypertension, switching from a dipeptidyl peptidase-4 (DPP-4) inhibitor to the sodium-glucose cotransporter-2 (SGLT2) inhibitor luseogliflozin appears to have favourable effects on blood pressure (BP), circadian rhythm, and night-time systolic BP (SBP) and pulse rate (PR), according to data from the open-label LUNA trial.
